Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01021956
Recruitment Status : Terminated (As two cases of retinal vascular occlusion in patients who received anti-VEGF)
First Posted : December 1, 2009
Last Update Posted : April 29, 2015
Information provided by (Responsible Party):
Steba Biotech S.A.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : May 2012
  Actual Study Completion Date : January 2014

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 20, 2016
May 27, 2016
2 November 18, 2016
January 13, 2017
3 October 3, 2017
November 2, 2017